Biotechnology & Medical Research

Page 1

ImmuPharma Plc 's subsidiary awarded 400,000 Euro Grant

Monday, 20 Oct 2014 02:00am EDT

ImmuPharma PLC:Says French region of Aquitaine has awarded ImmuPharma's subsidiary Ureka non-refundable grant of about e400,000 Euro.To develop Ureka's Urelix technology.Urelix technology is way to mimic natural peptides having helical conformation with artificial residues in order to strengthen this conformation and protect it from enzymatic degradation.

Portola Pharmaceuticals Inc announces commercial supply agreement for Andexanet Alfa With Lonza

Thursday, 16 Oct 2014 04:05pm EDT

Portola Pharmaceuticals Inc:Says that it has executed a supply agreement with Lonza for the commercial manufacturing of andexanet alfa.FDA-designated breakthrough therapy, andexanet alfa is the only recombinant Factor Xa molecule designed to specifically reverse the effects of oral and injectable Factor Xa inhibitors.It is being developed as an antidote for patients receiving one of these anticoagulants who either suffer from a major bleed or require emergency surgery.

Affymetrix Inc and Ariosa Diagnostics announce signing of multi-year supply agreement in support of Ariosa's Non-Invasive Prenatal Test

Thursday, 16 Oct 2014 06:30am EDT

Affymetrix Inc and Ariosa Diagnostics Inc:Announced the signing of a multi-year supply agreement covering Affymetrix arrays and instruments to be utilized as part of Ariosa's Harmony Non-Invasive Prenatal Test (NIPT).Says the partnership enables Ariosa to pursue the development of a Harmony test kit that will allow other laboratories around the world to adopt and perform this test.

Horizon Discovery Group PLC's Horizon CombinatoRx wins contract

Wednesday, 15 Oct 2014 02:00am EDT

Horizon Discovery Group PLC:Says Horizon CombinatoRx division has been contracted by top ten pharma company to profile lead oncology asset.Under terms of agreement, Horizon CombinatoRx will be paid about $450,000 (276,000 pounds) for work to be completed within six month period.Horizon will provide services to support proof-of-concept, monotherapy screening, and combination screening for the lead asset.Horizon CombinatoRx provides its partners access to unique cHTS platform and Chalice analytics software, which enable the screening and analysis of thousands of complementary drug combinations.Combined with Horizon's GENESIS (rAAV, CRISPR and ZFN) gene editing platform and X-MAN isogenic cell line technology, Horizon CombinatoRx offers services including novel phenotypic cell-based screens with compound siRNA, shRNA and sgRNA (for CRISPR based screening) libraries.

ilshinbiobase signs contract with Icoopnongsan

Wednesday, 15 Oct 2014 12:14am EDT

ilshinbiobase Co., Ltd:Signed a contract with Icoopnongsan, to supply lyophilizer.Contract amount of 355,450,000 won.

Sucampo Pharmaceuticals Inc announces extension of AMITIZA license and collaboration agreement with Takeda

Tuesday, 14 Oct 2014 06:45am EDT

Sucampo Pharmaceuticals Inc:Says on Oct. 9signs an amendment to existing collaboration and license agreement covering U.S and Canada for AMITIZA with Takeda Pharmaceutical Co Ltd.Amendment includes various modifications to collaboration agreement including extension of current term, minimum commercial investment during current term and various governance changes allowing Takeda additional flexibility in commercializing AMITIZA.During extended term, which will begin on Jan. 1, 2021, Takeda will split with Sucampo gross profits of branded AMITIZA for any dosage strength and form for the existing indications in the U.S. and Canada.In addition, on April 1, 2015 Takeda will no longer reimburse Sucampo for product details made by Sucampo sales representatives to healthcare professionals as well as other ancillary costs of sales force.

Oncodesign announces research agreement with Cellectis

Monday, 13 Oct 2014 11:45am EDT

Oncodesign SA:Announces a research agreement with Cellectis.Says it will do preclinical evaluation of drug candidates based on engineered cells developed by Cellectics as adoptive immunotherapy in fight against cancer.18-Month agreement is to continue preclinical collaboration initiated in 2013.Cellectis has also selected Oncodesign for preclinical studies of drug candidates from Cellectis' UCART portfolio of engineered allogeneic T Cells.Deal also concerns genome engineering.

Proteome Sciences plc signs $2 million contract with Genting TauRx Diagnostic Centre

Thursday, 25 Sep 2014 05:10am EDT

Proteome Sciences plc:Signs $2 mln contract with Genting TauRx Diagnostic Centre to develop diagnostic panels to detect Alzheimer's disease and monitor treatment efficacy London, Sept. 25, 2014.The project will involve PS analysing blood samples from patients enrolled in a phase 3 trial of the experimental Alzheimer's drug LMTX, targeting the tau pathway, and from age-matched controls.LMTX is being developed by TauRx Therapeutics for the treatment for Alzheimer's disease of mild to moderate severity.

Celltrion, Inc. signs contract with Celltrion Healthcare co.,Ltd

Thursday, 25 Sep 2014 02:32am EDT

Celltrion, Inc:Signs a contract with Celltrion Healthcare co.,Ltd to supply biosimilar antibody drug.Contract price for 80 bln won.

Markets

  • Sectors
  • U.S.
  • Europe
  • Asia

Sector Summary

Analyst Research

Report Title Price
Provider: Thomson Reuters StreetEvents
$75.00
Provider: Edison Investment Research
$10.00
Provider: Edison Investment Research
$10.00
Provider: Edison Investment Research
$10.00
Provider: Edison Investment Research
$10.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.